

Company Overview

Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to developing innovative therapeutics for the treatment of cancer. Rexahn currently has two clinical stage oncology candidates, RX-3117 and RX-5902 (Supinoxin™), and additional compounds in preclinical development to treat multiple types of cancer.

Rexahn Presents Updated Interim Data From Phase 2a Trial of RX-3117 in Advanced Bladder Cancer at the 2019 ASCO GU Symposium

Feb 19 2019, 8:00 AM EST

Rexahn Announces Presentations at the 2019 ASCO Genitourinary Cancers Symposium

Feb 6 2019, 8:00 AM EST

Rexahn Receives Notice of Allowance for U.S. Patent Covering RX-3117 Use in a Broad Range of Tumor Types

Feb 4 2019, 8:00 AM EST

Stock Overview

Symbol	RNN
Exchange	NYSE American
Market Cap	27.81m
Last Price	\$0.5761
52-Week	\$0.50 - \$2.38

02/20/2019 04:10 PM EST

Investor Relations

ir@rexahn.com

Management Team

Douglas J. Swirsky

President and Chief Executive Officer

Ely Benaim, M.D.

Chief Medical Officer

Lisa Nolan, Ph.D.

Chief Business Officer

Rexahn Pharmaceuticals, Inc.

15245 Shady Grove Road
Suite 455
Rockville, MD 20850

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.